[go: up one dir, main page]

MX9203762A - Administracion de monoaminacridinas en estados deficientes en colinergicos-neuronales. - Google Patents

Administracion de monoaminacridinas en estados deficientes en colinergicos-neuronales.

Info

Publication number
MX9203762A
MX9203762A MX9203762A MX9203762A MX9203762A MX 9203762 A MX9203762 A MX 9203762A MX 9203762 A MX9203762 A MX 9203762A MX 9203762 A MX9203762 A MX 9203762A MX 9203762 A MX9203762 A MX 9203762A
Authority
MX
Mexico
Prior art keywords
hydrogen
double bond
substituent
ethoxy
methoxy
Prior art date
Application number
MX9203762A
Other languages
English (en)
Inventor
William K Summers
Original Assignee
William K Summers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William K Summers filed Critical William K Summers
Publication of MX9203762A publication Critical patent/MX9203762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX9203762A 1986-10-01 1992-06-29 Administracion de monoaminacridinas en estados deficientes en colinergicos-neuronales. MX9203762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91407686A 1986-10-01 1986-10-01
US07/098,871 US4816456A (en) 1986-10-01 1987-09-24 Administration of monoamine acridines in cholinergic neuronal deficit states

Publications (1)

Publication Number Publication Date
MX9203762A true MX9203762A (es) 1992-09-01

Family

ID=26795215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203762A MX9203762A (es) 1986-10-01 1992-06-29 Administracion de monoaminacridinas en estados deficientes en colinergicos-neuronales.

Country Status (13)

Country Link
US (1) US4816456A (es)
EP (2) EP0328535B1 (es)
JP (1) JPH0655725B2 (es)
AT (1) ATE106245T1 (es)
AU (2) AU621035B2 (es)
CA (1) CA1335813C (es)
DE (2) DE3789967T2 (es)
DK (1) DK295888A (es)
FI (1) FI891548A (es)
HK (1) HK1001669A1 (es)
LU (1) LU88749I2 (es)
MX (1) MX9203762A (es)
WO (1) WO1988002256A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789678A (en) * 1986-08-25 1988-12-06 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing α-alkyl-4-amino-3-quinolinemethanols and 1-(4-aralkylamino-3-quinolinyl)alkanones and related compounds
US4897400A (en) * 1987-02-13 1990-01-30 Hoeschst-Roussel Pharmaceuticals, Inc. 9-amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds useful for incresing the cholinergic function in a mammal
EP0282959A3 (en) * 1987-03-17 1989-05-31 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 9-amino-tetrahydro-acridines and related compounds, a process for their preparation and their use as medicaments
US6075144A (en) * 1987-04-20 2000-06-13 Hoechst Marion Roussel, Inc. 9-hydroxyamino tetrahydroacridine and related compounds
US5013741A (en) * 1987-09-08 1991-05-07 Hoechst-Roussel Pharmaceuticals Incorporated N-[substituted alkylidene]-1,2,3,4-tetrahydro-9-acridinamines useful for enhancing the cholinergic function in a mammal
US5037833A (en) * 1988-07-25 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. N-[substituted alkylidene]fused-bicycloalkylidene quinolinamines useful for enhancing the cholinergic function in a mammal
US5008853A (en) 1987-12-02 1991-04-16 Xerox Corporation Representation of collaborative multi-user activities relative to shared structured data objects in a networked workstation environment
DE3889302T2 (de) 1987-12-03 1994-10-20 Mitsubishi Chem Ind 9-(Acylamino)tetrahydroacridinderivate und wahrnehmungssteigernde Mittel davon als aktiver Wirkstoff.
IE62871B1 (en) * 1988-03-08 1995-03-08 Warner Lambert Co Compositions with enhanced penetration
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
JPH02180871A (ja) * 1988-11-16 1990-07-13 Hoechst Roussel Pharmaceut Inc ヒドロキシ―１，２，３，４―テトラヒドロアミノアクリジンおよびその製造法
FR2651230B1 (fr) * 1989-08-25 1992-03-13 Synthese Rech Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments.
US4994452A (en) * 1989-11-28 1991-02-19 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5112829A (en) * 1989-11-28 1992-05-12 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5508280A (en) * 1990-05-18 1996-04-16 Merrell Pharmaceuticals, Inc. 5H-Dibenzo (A,D) cycloheptenes as muscarinic receptor antagonists
US5610155A (en) * 1992-04-09 1997-03-11 Dr. Karl Thomae Gmbh Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation
US5466696A (en) * 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
US5422350A (en) * 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
DE19533089C1 (de) * 1995-09-07 1997-05-22 Hexal Ag Tacrin-Pflaster
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
GB9524346D0 (en) * 1995-11-29 1996-01-31 Univ Strathclyde Polycyclic compounds
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
US5929093A (en) * 1996-06-13 1999-07-27 Mayo Foundation For Medical Education And Research Bifunctional acetylcholinesterase reactivators
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
MXPA02009948A (es) * 2000-05-04 2003-02-12 Warner Lambert Co Metodo para la inhibicion de la agregacion de la proteina amiloide y la formacion de imagenes de los depositos amiloides usando derivados aminoindanos.
US20040087658A1 (en) * 2002-10-24 2004-05-06 Hans-Joerg Moebius Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2005072713A2 (en) 2004-01-27 2005-08-11 The Feinstein Institute For Medical Research Cholinesterase inhibitors for treating inflammation
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
CA2589102C (en) * 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
EP2015750A2 (en) * 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
NO3034079T3 (es) 2010-11-15 2018-06-09
US9459187B2 (en) 2011-03-04 2016-10-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CA2934553C (en) 2013-12-20 2023-10-31 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
US10815242B2 (en) 2015-06-19 2020-10-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7412177B2 (ja) * 2018-02-19 2024-01-12 國子 草間 バレロラクトン（Ｖａｌｅｒｏｌａｃｔｏｎｅ）系新規化合物、及び、医薬
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
KR101953366B1 (ko) 2018-12-26 2019-02-28 정종문 침향을 포함하는 기억력 및 인지능력을 향상시키는 기능성 건강식품 및 이의 제조방법
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1629873A (en) * 1919-07-08 1927-05-24 Ig Farbenindustrie Ag Acridine derivatives and process of making same
US2083908A (en) * 1933-03-23 1937-06-15 Hata Sahachiro Method of preparing 9-amino-3, 6-dimethoxy-10-methyl-acridinium chlorides
US2083903A (en) * 1936-04-27 1937-06-15 Gerald William G Fitz Tire chain
US3043842A (en) * 1959-02-09 1962-07-10 Smith Kline French Lab Substituted acridans
CH420150A (de) * 1961-12-18 1966-09-15 Siegfried Ag Verfahren zur Herstellung von 10-Aminoalkyl-5,5-dialkylacridanen
NL6603826A (es) * 1965-03-24 1966-09-26
DE1251764B (de) * 1965-08-18 1967-10-12 C H Boehnnger Sohn Ingelheim/ Rhein Verfahren zur Herstellung von antimikrobiell wirksamen 12 3,4-Tetra hydro 9 -ammo acridmiumverbmdungen
US3489837A (en) * 1968-07-11 1970-01-13 Leroy J Hyman Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride
DE3582995D1 (de) * 1984-10-25 1991-07-04 Hoechst Roussel Pharma 9-amino-1,2,3,4-tetrahydroacridin-1-ol und verwandte verbindungen, verfahren zu ihrer herstellung und verwendung als arzneimittel.
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds

Also Published As

Publication number Publication date
JPH02500975A (ja) 1990-04-05
AU8070787A (en) 1988-04-21
WO1988002256A1 (en) 1988-04-07
EP0595365A1 (en) 1994-05-04
CA1335813C (en) 1995-06-06
FI891548A0 (fi) 1989-03-31
EP0328535A4 (en) 1991-05-22
FI891548A (fi) 1989-03-31
EP0328535A1 (en) 1989-08-23
US4816456A (en) 1989-03-28
DE3789967T2 (de) 1994-09-22
AU621035B2 (en) 1992-03-05
ATE106245T1 (de) 1994-06-15
HK1001669A1 (en) 1998-07-03
AU7888694A (en) 1995-02-09
DE19575031I2 (de) 2003-05-22
DK295888A (da) 1988-06-07
DK295888D0 (da) 1988-05-31
AU671933B2 (en) 1996-09-12
JPH0655725B2 (ja) 1994-07-27
EP0328535B1 (en) 1994-06-01
DE3789967D1 (de) 1994-07-07
LU88749I2 (fr) 1996-08-23

Similar Documents

Publication Publication Date Title
MX9203762A (es) Administracion de monoaminacridinas en estados deficientes en colinergicos-neuronales.
MY101541A (en) Indolizine derivatives, process for preparing them and the compositions containing them
ATE289602T1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
MY108885A (en) Heterocyclic-cyclic amine derivatives.
NO175592C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner
ES468119A1 (es) Un procedimiento para la preparacion de triazinas
ATE129714T1 (de) Heterocyclische biphosphonsäurederivate.
EP0614661A3 (en) Benzylidene and cinnamylidene malononitrile derivatives to inhibit proliferative processes in mammalian cells.
MY104335A (en) 4-aminophridine deravatives
DE69227088D1 (de) Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln
HUP0100184A2 (hu) Szubsztituált 2-(benzil-amino)-2-fenil-acetamid-vegyületek és ezeket tartalmazó gyógyszerkészítmények
ES8303355A1 (es) Procedimiento para la obtencion de nuevos derivados de mer- captoimidazoles.
TR199902350T2 (xx) Yeni piridin t�revleri ve onlardan olu�an farmakotik bile�imler.
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
NO995638L (no) Heterobicykliske forbindelser til fremstilling av pyridonkarboksylsyrederivater
EP0309425A3 (en) New heterocyclic derivatives
ATE5961T1 (de) N-acylpeptid-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE123487T1 (de) Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen.
ATE278676T1 (de) Imdazol-derivate, deren herstellung und deren verwendung als s-adenosylmethionin decarboxylase (=samdc) inhibitoren
FR2694557B1 (fr) Dérivés de tétrahydronaphtalène, leur préparation, et leur application en thérapeutique.
NZ220543A (en) Ergoline derivatives and pharmaceutical compositions
FR2695643B1 (fr) Dérivés d'uréido-acétamide, leur préparation et les médicaments les contenant.
ES2056025A1 (es) Nuevos derivados de indol.
PL304334A1 (en) Pharmaceutical composition of gastric protective action, including antiulceric one and method of treating diseases of gastrointestinal tract